Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC ...

Shortly after President-elect Donald J. Trump nominated Robert F. Kennedy Jr. to lead the Department of Health and Human ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax shares are trading higher by 12.4% during Tuesday's session. A recent CDC report highlights a sharp increase in ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $10.82 which represents a slight increase of $1.06 or 10.86% from the prior close of $9.76. The stock opened at $9.95 and touched a low ...

(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

The stock's fall snapped a five-day winning streak.

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.28 which represents a decrease of $-0.19 or -2.24% from the prior close of $8.47. The stock opened at $8.44 and touched a low of ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. Things were looking up for Novavax stock after the FDA ...